Detalles de la búsqueda
1.
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol
; 17(4): 452-463, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26973324
2.
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Blood
; 124(5): 729-36, 2014 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-24948656
3.
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Cancer
; 118(1): 118-26, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21732337
4.
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Lancet Haematol
; 3(12): e581-e591, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27890073
5.
Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom.
Leuk Lymphoma
; 55(8): 1870-5, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24313831
6.
The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.
Patient
; 6(2): 81-92, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529848
7.
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Leuk Lymphoma
; 53(5): 907-14, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22023530
Resultados
1 -
7
de 7
1
Próxima >
>>